Skip to main content
. Author manuscript; available in PMC: 2015 Apr 29.
Published in final edited form as: Breast Cancer Res Treat. 2014 Nov 14;148(3):571–580. doi: 10.1007/s10549-014-3191-4

Fig. 2.

Fig. 2

CYP2D6 and CYP2C9 phenotypes in Hispanic and NHW breast cancer patients. CYP2D6 and CYP2C9 phenotypes were assessed within Hispanics and NHWs. CYP2D6 activity was also assessed using a scoring system that incorporates CYP2D6 genetic variation and CYP2D6 mediated drug–drug interactions, in which the activity score (AS) is the product of the gene score (GS) based on the enzyme genotype and the inhibitor factor (IF) of concurrent medications taken by the patients in use of TAM [32] (Fig. 2a, insert). EM extensive metabolizers, IM intermediate metabolizers, PM poor metabolizers. For CYP2D6, n = 65 (Hispanics) and n = 178 (NHWs), and for CYP2C9, n = 74 (Hispanics) and n = 186 (NHWs). CYP2C9 PM was not included on the statistical analyses due to the low frequency of the phenotype in both ethnicities. Data are expressed as phenotype frequencies (%). Statistical significance was verified applying the z score/Chi square test (p ≥ 0.05)